Seres Therapeutics bolsters balance sheet with $25M Nestlé deal, extends runway into 2027

Seres Therapeutics (NASDAQ:MCRB) announced a series of strategic financial moves aimed at strengthening its liquidity position.

The company has finalized a transaction with Nestlé Health Science and restructured its core facility lease, steps the firm says will extend its operating cash runway well into the first quarter of 2027.

Under the amended asset purchase agreement, Nestlé Health Science will pay Seres a total of $25 million to buy out all potential future milestone payments related to the net sales of VOWST.

The funds are scheduled to be paid in two equal installments of $12.5 million each on July 1, 2026, and October 1, 2026.

Seres originally sold the VOWST business to Nestlé in 2024.

Complementing the capital influx, Seres has restructured the lease for its corporate facility at 101 CambridgePark Drive in Cambridge, Massachusetts.

The new 10-year agreement, effective May 1, 2026, significantly reduces the company’s leased footprint.

By lowering its rental rates and shared operating expenses, Seres expects to materially decrease its long-term lease obligations and ongoing annual facility-related cash expenditures.

As of March 31, 2026, Seres reported a cash and cash equivalents balance of $29.8 million.

Management stated that these combined transactions provide the necessary capital to sustain operations while the company continues to advance its pipeline of live biotherapeutic products for inflammatory and immune diseases.

The company is currently preparing for a near-term clinical milestone, with data from an investigator-sponsored study of SER-155 in patients with immune checkpoint inhibitor-related enterocolitis expected to be released later this month.